Sino Biopharmaceutical Ltd
Company Profile
Business description
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm’s biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
Contact
1 Harbour Road
Unit 09, 41st Floor, Office Tower, Room 4109
Convention Plaza
Wanchai
Hong Kong
HKGT: +852 28029886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
24,437
Stocks News & Analysis
video
Can this fallen ASX star shine again?
stocks
Ask the analyst: Are Telix's growth prospects priced in?
stocks
How to build an income portfolio
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,598.60 | 69.10 | 0.81% |
| CAC 40 | 7,545.66 | 56.40 | -0.74% |
| DAX 40 | 19,538.98 | 30.69 | 0.16% |
| Dow JONES (US) | 43,065.22 | 201.36 | 0.47% |
| FTSE 100 | 8,263.53 | 29.13 | -0.35% |
| HKSE | 20,318.79 | 774.08 | -3.67% |
| NASDAQ | 18,502.69 | 159.75 | 0.87% |
| Nikkei 225 | 39,910.55 | 304.75 | 0.77% |
| NZX 50 Index | 12,840.77 | 74.02 | 0.58% |
| S&P 500 | 5,859.85 | 44.82 | 0.77% |
| S&P/ASX 200 | 8,318.40 | 65.60 | 0.79% |
| SSE Composite Index | 3,201.29 | 83.03 | -2.53% |